Genmab Finalizes Tender Offer for Dutch Biotech Merus

MT Newswires · 2d ago
02:34 AM EST, 12/12/2025 (MT Newswires) -- Genmab (GMAB.CO) unit Genmab Holding II concluded its tender offer for Dutch clinical-stage immuno-oncology company Merus. The Danish biotechnology company said Friday that 94.2% of Merus shares were validly tendered and accepted for payment. A subsequent offer to buy remaining Merus shares will commence on Friday, according to a same-day release. The subsequent offer, priced similarly at $97 per Merus share in cash, will run until Dec. 29.